4-amino-1,8-naphthalimide on the Sensitive Effect of Arsenic Trioxide in Hepatocellular Carcinoma Cells

LI Yang, LUO Qing-ying, DENG Jian-jun. et al

Abstract

To study the effect and mechanism of 4-amino-1,8-naphthalimide(4-AN) on the sensitive effect of arsenic trioxide (ATO) in hepatocellular carcinoma cells. Methods Hepatocellular carcinoma HepG2 cells were divided into two groups according to whether they were treated with 4-AN or not. Cell viability was evaluated by MTT assay, population doubling experiment and colony formation assay; genic mechanism was explored by 8-OH-dG assay, single cell gel electrophoresis (comet assay) and micronucleus test. Results At 2-10 μmol/L concentration of ATO, the cell viability and colony formation efficiency of the combination group (4-AN+ATO) were significantly lower than that of the ATO group (\P\P\P\P\P<0.05). Conclusion 4-AN can significantly increase the sensitivity of ATO in treatment with hepatocellular carcinoma cells and prevent DNA damage repair may be a primary mechanism for this effect.

 

Keywords: Hepatocellular carcinoma, Arsenic trioxide, Poly (ADP-ribose) polymerase-1 

 

Full Text:

PDF


References


Lin LM. Li BX, Xiao JB, et al. Synergistic effect of all-trans- retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol, 2005 ; 11(36); 5633-5637.

Liu JX, Zhou GB, Chen SJ, etal. Arsenic compounds: revived ancient remedies in the fight against human malignancies. Curr Opin Chem Biol,2012; 16( 1-2) :92-98.

Chen C, Jiang X, Hu Y, et al. The protective role of resveratrol in the sodium arsenite-induced oxidative damage via modulation of intracellular GSH homeostasis. Biol Trace Elem Res,2013;155(1):119-131.

Ma ZB, Xu HY, Jiang M, et al. Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells. World J Gastroenterol, 2014;20(18) ; 5505-5510.

Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors; anticancer therapy and beyond. Mol Aspects Med, 2013;34(6);1217-1256.

Shi Y, Zhou F, Jiang F. et al. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. Chin J Cancer Res,2014;26(2); 142-147.

Wielgos M, Yang ES. Discussion of PARP inhibitors in cancer therapy. Pharm Pat Anal,2013;2(6);755-766.

Shah GM, Robu M, Purohit NK. et al. PARP inhibitors in cancer therapy; magic bullets but moving targets. Front Oncol, 2013 Nov 14; 3; 279. doi: 10. 3389/fonc. 2013. 0027. eCollection 2013.

Liu HH. Lin MH. Liu PC, et al. Health risk assessment by measuring plasma malondialdehyde ( MDA ), urinary 8- hydroxydeoxyguanosine (8-OH-dG) and DNA strand breakage following metal exposure in foundry workers. J Hazard Mater, 2009;170(2-3):699-704.


Refbacks

  • There are currently no refbacks.